CRNX Stock Summary and Trading Ideas (Crinetics Pharmaceuticals | NASDAQ:CRNX)

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Crinetics Pharmaceuticals trades on the NASDAQ stock market under the symbol CRNX.

As of March 11, 2026, CRNX stock price declined to $36.98 with 753,597 million shares trading.

CRNX has a beta of 1.47, meaning it tends to be more sensitive to market movements. CRNX has a correlation of 0.17 to the broad based SPY ETF.

CRNX has a market cap of $3.79 billion. This is considered a Mid Cap stock.

Last quarter Crinetics Pharmaceuticals reported $6 million in Revenue and -$1.29 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.08.

In the last 3 years, CRNX traded as high as $62.53 and as low as $15.23.

The top ETF exchange traded funds that CRNX belongs to (by Net Assets): VTI, VB, IWM, VBK, VXF.

CRNX has underperformed the market in the last year with a price return of +9.6% while the SPY ETF gained +21.9%. CRNX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -23.1% and -16.9%, respectively, while the SPY returned -1.3% and -1.6%, respectively.

CRNX support price is $36.06 and resistance is $38.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRNX shares will trade within this expected range on the day.